PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27388042-9	2017	The doxorubicin cardioprotective agent dexrazoxane partially protected myocytes from doxorubicin plus bortezomib or carfilzomib treatment, in spite of the fact that bortezomib and carfilzomib inhibited the dexrazoxane-induced decreases in topoisomerase IIbeta protein levels in myocytes.	Dexrazoxane	39-50	DNA topoisomerase II beta	Rattus norvegicus	239-259	
28941780-0	2017	Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite.	Dexrazoxane	23-34	DNA topoisomerase II beta	Rattus norvegicus	102-122	
28941780-5	2017	Although chemical instability is an obstacle for the development of JR-311, this study identified a novel dexrazoxane analogue with preserved pharmacodynamic properties, contributed to the investigation of structure-activity relationships and suggested that the cardioprotection of bis-dioxopiperazines is likely attributed to TOP2B activity of the parent compound rather than Fe chelation of their hydrolytic metabolites/degradation products.	Dexrazoxane	106-117	DNA topoisomerase II beta	Rattus norvegicus	327-332	
31773441-0	2020	The Role of Topoisomerase IIbeta in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane.	Dexrazoxane	103-114	DNA topoisomerase II beta	Rattus norvegicus	12-32	
31773441-5	2020	However, a competing hypothesis posits that dexrazoxane may be protective through its ability to inhibit and reduce topoisomerase IIbeta protein levels in the heart.	Dexrazoxane	44-55	DNA topoisomerase II beta	Rattus norvegicus	116-136	
31773441-9	2020	Dexrazoxane treatment resulted in an almost complete reduction of topoisomerase IIbeta in the nucleus and a lesser reduction in the cytoplasm.	Dexrazoxane	0-11	DNA topoisomerase II beta	Rattus norvegicus	66-86	
31773441-10	2020	The recovery of topoisomerase IIbeta levels after a pulse topoisomerase IIbeta inhibitory concentration of dexrazoxane occurred slowly, with partial recovery only occurring after 24 h. The ability of dexrazoxane to reduce doxorubicin-induced damage to myocytes was greatest when topoisomerase IIbeta levels were at their lowest.	Dexrazoxane	107-118	DNA topoisomerase II beta	Rattus norvegicus	58-78	
31773441-10	2020	The recovery of topoisomerase IIbeta levels after a pulse topoisomerase IIbeta inhibitory concentration of dexrazoxane occurred slowly, with partial recovery only occurring after 24 h. The ability of dexrazoxane to reduce doxorubicin-induced damage to myocytes was greatest when topoisomerase IIbeta levels were at their lowest.	Dexrazoxane	107-118	DNA topoisomerase II beta	Rattus norvegicus	58-78	
31773441-10	2020	The recovery of topoisomerase IIbeta levels after a pulse topoisomerase IIbeta inhibitory concentration of dexrazoxane occurred slowly, with partial recovery only occurring after 24 h. The ability of dexrazoxane to reduce doxorubicin-induced damage to myocytes was greatest when topoisomerase IIbeta levels were at their lowest.	Dexrazoxane	200-211	DNA topoisomerase II beta	Rattus norvegicus	16-36	
31773441-10	2020	The recovery of topoisomerase IIbeta levels after a pulse topoisomerase IIbeta inhibitory concentration of dexrazoxane occurred slowly, with partial recovery only occurring after 24 h. The ability of dexrazoxane to reduce doxorubicin-induced damage to myocytes was greatest when topoisomerase IIbeta levels were at their lowest.	Dexrazoxane	200-211	DNA topoisomerase II beta	Rattus norvegicus	58-78	
31773441-10	2020	The recovery of topoisomerase IIbeta levels after a pulse topoisomerase IIbeta inhibitory concentration of dexrazoxane occurred slowly, with partial recovery only occurring after 24 h. The ability of dexrazoxane to reduce doxorubicin-induced damage to myocytes was greatest when topoisomerase IIbeta levels were at their lowest.	Dexrazoxane	200-211	DNA topoisomerase II beta	Rattus norvegicus	58-78